Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Systemic-onset juvenile idiopathic arthritis (Still’s disease) is a rare and serious form of arthritis that affects children. It causes inflammation not only in the joints, but also in other organs such as the liver, heart, and lungs. It is also known as systemic juvenile rheumatoid arthritis or juvenile-onset Still’s disease. The main symptoms of this condition are high fever, rash, and arthritis. The fever usually occurs daily or twice a day, and the rash is salmon-pink and migrates to different parts of the body. Arthritis may develop later in the course of the disease and affect both large and small joints. Other symptoms may include enlargement of the liver, spleen, or lymph nodes; anemia; and inflammation of the lining of the chest or abdomen. The cause of this condition is unknown, but it may be related to genetic, environmental, and hormonal factors. It is diagnosed by excluding other possible causes of fever and arthritis, and by testing for blood markers of inflammation. Treatment options include glucocorticoids, methotrexate, anakinra, and tocilizumab. These drugs can help reduce inflammation and prevent complications such as growth problems, joint damage, or organ failure.
The Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 36 molecules, with 34 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAbbVie Inc
Aprilbio Co Ltd
Bio-Thera Solutions Ltd
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Changchun GeneScience Pharmaceutical Co Ltd
Delta 4 GmbH
DNX Biopharmaceuticals Inc
Eli Lilly and Co
Fresenius Kabi SwissBioSim GmbH
IcanoMAB GmbH
Immutep Ltd
IMMvention Therapeutix Inc
Intas Pharmaceuticals Ltd
Intrinsic Medicine Inc
JSR Life Sciences LLC
Mesenbio Ltd
Minapharm Pharmaceuticals
Mycenax Biotech Inc
NeuClone Pty Ltd
Novartis AG
Pfizer Inc
Pharmapraxis
Regeneron Pharmaceuticals Inc
Sandoz Group AG
Shilpa Biologicals Pvt Ltd
Swedish Orphan Biovitrum AB
University of Colorado
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang University
Table of Contents
Table
Figures
Frequently asked questions